Secondary screening for systemic lupus erythematosus (SLE) based on ANA results.
Semi-Quantitative Indirect Fluorescent Antibody
New York DOH Approval Status
Serum separator tube.
Separate serum from cells ASAP or within 2 hours of collection. Transfer 1 mL serum to an ARUP Standard Transport Tube. (Min: 0.15 mL)
Plasma. Cerebral spinal fluid. Contaminated, hemolyzed, or severely lipemic specimens.
After separation from cells: Ambient: 48 hours; Refrigerated: 2 weeks; Frozen: 1 year (avoid repeated freeze/thaw cycles)
Less than 1:10
Positivity for anti-double stranded DNA (anti-dsDNA) IgG antibody is a diagnostic criterion of systemic lupus erythematosus (SLE). The presence of the anti-dsDNA IgG antibody is identified by IFA titer (Crithidia luciliae indirect fluorescent test [CLIFT]). CLIFT is highly specific for SLE with a sensitivity of 50-60 percent.
Some patients with early or inactive SLE may be positive for anti-dsDNA IgG by ELISA but negative by CLIFT. If the CLIFT result is negative but the patient has a positive ELISA and clinical suspicion remains, consider antinuclear antibody (ANA) testing by IFA. Additional information and recommendations for testing may be found at https://www.arupconsult.com/Topics/AutoimmuneDz/ConnectiveTissueDz/index.html.
Double Stranded DNA (dsDNA) antibodies (1:10 or greater) are found in 50-60 percent of systemic lupus erythematosus (SLE), 20-30 percent in Sjögren syndrome, 20-25 percent in mixed connective tissue disease (MCTD), and less than 5 percent in progressive systemic sclerosis (PSS). High titers of antibody to native (double stranded) DNA are specific for SLE.
|Component Test Code*||Component Chart Name||LOINC|
|2002692||Double-Stranded DNA (dsDNA) Ab IgG IFA||58466-4|
- Antibody to ds-DNA
- Crithidia luciliae indirect fluorescent test (CLIFT)
- Double stranded DNA antibody
- Native double-stranded DNA antibody